Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MK-6194 in Healthy Chinese Participants
NCT06821334Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Primary completion
- Aug 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PT101 in systemic lupus erythematosus (SLE) and Vitiligo (3 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event and Number of Participants Who Discontinue Study Due to an AE. Started Apr 2024; status: completed.
02
Drugs
PT101
03
Conditions
systemic lupus erythematosus (SLE)Vitiligo
Beyond the preview
Go deeper on NCT06821334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821334.